Small-animal PET imaging of human epidermal growth factor receptor type 2 expression with site-specific 18F-labeled protein scaffold molecules

Journal of Nuclear Medicine

Volumn 49, Issue 5, 2008, Pages 804-813

  Cheng, Zhen ^a   De Jesus, Omayra Padilla ^b   Namavari, Mohammad ^a   De, Abhijit ^a   Levi, Jelena ^a   Webster, Jack Matt ^b   Zhang, Rong ^b   Lee, Brian ^b   Syud, Faisal A ^b   Gambhir, Sanjiv Sam ^a  

^a STANFORD UNIVERSITY   (United States)

^b GENERAL ELECTRIC COMPANY   (United States)

Author keywords

18F; Affibody; HER2; Imaging; PET

Indexed keywords

4 FLUOROBENZALDEHYDE F 18; DIMER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORINE 18; N (4 FLUOROBENZYLIDENE)OXIME F 18; OXIME; PROTEIN; RADIOPHARMACEUTICAL AGENT; TRASTUZUMAB; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BIOACCUMULATION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; EARLY DIAGNOSIS; EXPERIMENTAL MOUSE; FEMALE; FLUORINATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MOLECULAR IMAGING; MOLECULAR PROBE; MOLECULE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOCHEMISTRY; TISSUE DISTRIBUTION; TUMOR DIAGNOSIS; TUMOR MODEL; TUMOR RECURRENCE;

ANIMALS; CELL LINE, TUMOR; DIMERIZATION; FLUORINE RADIOISOTOPES; GENE EXPRESSION REGULATION; HALOGENATION; HUMANS; MICE; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; PROTEIN STRUCTURE, QUATERNARY; RADIOCHEMISTRY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; SUBSTRATE SPECIFICITY; TISSUE DISTRIBUTION;

EID: 44149108464     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.047381     Document Type: Article

References (29)

1. Meric-Bernstam F, Hung MC. Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy. Clin Cancer Res. 2006;12:6326-6330.
2. Ferretti G, Felici A, Papaldo P, Fabi A, Cognetti F. HER2/neu role in breast cancer: from a prognostic foe to a predictive friend. Curr Opin Obstet Gynecol. 2007;19:56-62.
3. Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol. 2004;22:701-706.
4. 111In- trastuzumab (Herceptin) Fab fragments. Nucl Med Biol. 2005;32:51-58.
5. Baum R, Orlova A, Tolmachev V, Feldwisch J. Receptor PET/CT and SPECT using an Affibody molecule for targeting and molecular imaging of HER2-positive cancer in animal xenografts and human breast cancer patients [abstract]. J Nucl Med. 2006;47(suppl):108P.
6. Orlova A, Tolmachev V, Pehrson R, et al. Synthetic Affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res. 2007;67:2178-2186.
7. 177Lu-labeled HER2-specific Affibody molecule. Cancer Res. 2007;67:2773-2782.
8. Orlova A, Magnusson M, Eriksson TL, et al. Tumor imaging using a picomolar affinity HER2 binding Affibody molecule. Cancer Res. 2006;66:4339-4348.
9. 99mTc to tumor-targeting Affibody molecules. Bioconjug Chem. 2007;18:549-558.
10. HER2:342, an Affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. J Nucl Med. 2006;47:846-853.
11. Orlova A, Nilsson FY, Wikman M, et al. Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 Affibody for single-photon imaging of HER2 expression in tumors. J Nucl Med. 2006;47:512-519.
12. 2:342), an Affibody ligand conjugate for targeting of HER2-expressing malignant tumors. Q J Nucl Med Mol Imaging. 2007;51:1-10.
13. 2:342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma. Int J Mol Med. 2007;19:285-291.
14. Mume E, Orlova A, Larsson B, et al. Evaluation of ((4-hydroxyphenyl) ethyl) maleimide for site-specific radiobromination of anti-HER2 Affibody. Bioconjug Chem. 2005;16:1547-1555.
15. 211At labeled HER-2 binding Affibody molecules in mice. Oncol Rep. 2007;17:1141-1147.
16. Artemov D, Mori N, Ravi R, Bhujwalla ZM. Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res. 2003;63:2723-2727.
17. Hilger I, Leistner Y, Berndt A, et al. Near-infrared fluorescence imaging of HER-2 protein over-expression in tumour cells. Eur Radiol. 2004;14:1124-1129.
18. Tada H, Higuchi H, Wanatabe TM, Ohuchi N. In vivo real-time tracking of single quantum dots conjugated with monoclonal anti-HER2 antibody in tumors of mice. Cancer Res. 2007;67:1138-1144.
19. Nilsson FY, Tolmachev V. Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy. Curr Opin Drug Discov Devel. 2007;10:167-175.
20. Wikman M, Steffen AC, Gunneriusson E, et al. Selection and characterization of HER2/neu-binding Affibody ligands. Protein Eng Des Sel. 2004;17:455-462.
21. Okarvi SM. Recent progress in fluorine-18 labelled peptide radiopharmaceuticals. Eur J Nucl Med. 2001;28:929-938.
22. 18F-labeled RGD and octreotide analogs. J Nucl Med. 2004;45:892-902.
23. 64Cu- Labeled alpha-melanocyte-stimulating hormone analog for microPET imaging of melanocortin 1 receptor expression. Bioconjug Chem. 2007;18:765-772.
24. Verel I, Visser GW, van Dongen GA. The promise of immuno-PET in radioimmunotherapy. J Nucl Med. 2005;46(suppl):164S-171S.
25. Rothe A, Hosse RJ, Power BE. In vitro display technologies reveal novel biopharmaceutics. FASEB J. 2006;20:1599-1610.
26. Uchiyama F, Tanaka Y, Minari Y, Tokui N. Designing scaffolds of peptides for phage display libraries. J Biosci Bioeng. 2005;99:448-456.
27. Ladner RC. Polypeptides from phage display: a superior source of in vivo imaging agents. Q J Nucl Med. 1999;43:119-124.
28. 18F-labeled T84.66 anti-carcinoembryonic antigen diabody. J Nucl Med. 2007;48:304-310.
29. 3 expression in living mice. Bioconjug Chem. 2005;16:1433-1441.